Amarin’s vascepa shows cardiovascular efficacy in published trial

Amarin (AMRN) highlighted recently published data in the Journal of the American Heart Association showing in a post-hoc analysis of the REDUCE-IT study that, among statin-treated patients with elevated triglycerides and high cardiovascular risk, vascepa/vazkepa – icosapent ethyl or IPE – reduced composite cardiovascular endpoint events regardless of baseline levels of low-density lipoprotein cholesterol. IPE, which is the active ingredient in vascepa, significantly reduced the primary composite endpoint of cardiovascular events by 34% among patients with very well-controlled LDL-C. Elevated LDL-C is a well-established major CV risk factor supported by clinical evidence showing decreased atherosclerotic disease events when LDL-C is therapeutically lowered. Data from REDUCE-IT has consistently shown robust relative and absolute risk reductions in the primary analyses and several sub-group analyses which led to incorporation of IPE in multiple guidelines and consensus statements globally.